). This was significantly (P<0.01) higher than the mean value of control subjects. The mean SCE frequencies in 3 of these 7 patients fell within the control range and in 4 of these patients was above the control range. These results suggest that some immunosuppressed kidney transplant recipients are liable to chromosomal damage.
An increased incidence of cancer is well recognized in renal transplant recipients (Penn, 1979; Sheil et al., 1981) . In these patients, tumours arise predominantly in the skin, uterine cervix and lymphoid tissue although primary tumours in a wide variety of other sites also occur at a higher incidence than in an age-matched group in the general community. A number of hypotheses have been proposed to explain this phenomenon, generally relating either to immune dysfunction associated with immunosuppressive therapy, or to the antigenic stimulation of the graft (Sheil, 1982) . Another factor which may be involved is chemical carcinogenicity of immunosuppressive agents. It is to this last possibility that this study is addressed.
A wide variety of drugs and agents are used in transplantation to achieve immunosuppression, including azathioprine, corticosteroids, antilymphocyte globulin, actinomycin C, cyclosporin A and cyclophosphamide. Of these, a combination of azathioprine (Imuran: Burroughs Wellcome) and corticosteroids is the usual immunosuppressive regimen. Of these, azathioprine has been reported to be mutagenic in the Ames test (Speck & Rosenberg, 1976) and in a variety of in vivo and in vitro cellular assays (Pederson, 1964; Nasjleti & Spencer, 1966; Ripps et al., 1971; Clark, 1975; Wyrobek & Bruce, 1975; Krogh-Jensen & Hiittle, 1976; Van Went, 1979) as well as being teratogenic (Thiersch, 1962; Githers et al., 1965 non-transplant patients receiving azathioprine therapy for a variety of disorders. An increased incidence of chromosomal abnormalities (including chromatid or chromosomal breaks, fragments and rearrangements) has been reported in some patients (Krogh-Jensen, 1967 , 1970 Krogh-Jensen & Soborg, 1966; Eberle et al., 1968) but the increased incidence was not uniform and it is difficult to separate the chromosomal damage in those patients due to azathioprine and that due to the primary disease process. There are few reports of similar studies in transplant recipients. In one study of renal transplant recipients receiving azathioprine/prednisone therapy (Kingston et al., 1971) , an increased incidence of chromosomal damage was reported in peripheral blood lymphocytes (PBL) in some recipients, but this was attributed to the adjunct radiotherapy that these patients received rather than to the chemotherapy. In one other report, an increased incidence of chromosomal abnormalities was observed in PBL from both a renal transplant recipient and the new born child of that recipient (Leb et al., 1971) . In this study, chromosome studies were performed on PBL from renal transplant recipients who were on maintenance doses of azathioprine and prednisone and were from 6 months to 9 years post-transplantation; some of these patients developed skin cancer (squamous cell carcinoma and basal cell carcinoma) following transplantation. The purpose of the study was to see if there was any evidence of chromosomal damage in kidney transplant recipients and to relate this to the development of skin cancer.
Chromosomal damage can be investigated using the technique of sister chromatid exchange (SCE). SCE involves the breaking and crossing of a segment of deoxyribonucleic acid (DNA) between 2 sister chromatids. While the precise molecular basis of SCE and its relationship to mutagenesis remain unclear, there is mounting evidence that the SCE assay is a reliable indicator of whole body exposure to mutagenic and carcinogenic chemicals (Perry & Evans, 1975; Nevstad, 1978; Raposa, 1978) although not of radiation (Perry & Evans, 1975) . While the relationship between SCE induction and chromosomal aberration induction is complex, SCE frequency appears to be a more sensitive assay of chromosome-damaging agents than other commonly used assays such as morphological chromosome studies and presence of micro-nuclei; moreover the in vivo effects of mutagenic chemicals are more readily detected by SCE frequency at drug doses which cause almost no morphological chromosome damage (Latt, 1974; Perry & Evans, 1975; Abe & Sasaki, 1977 Fifty-six kidney transplant recipients were tested. The selection and management of these patients has been described elsewhere (Sheil et al., 1972) . Each patient had stable graft function and was receiving maintenance azathioprine (1-2mgkg-1) and prednisone (0.2-0.5mgkg-1) therapy; most patients had received a short course of goat anti-human lymphocyte globulin immediately following transplantation. Patients with a blood lymphocyte count <500 cells mm 3 were excluded from the study; otherwise the 56 patients were randomly selected from a large pool of transplant recipients. 
Results
The reproducibility of the SCE assay is high. Three control subjects tested on 3-4 occasions at monthly intervals each displayed little variation in mean SCE frequency (Table I) . A one-way analysis of variance on these data indicated no significant difference (P>0.05) between tests. However, not all PBL samples from the study group responded adequately to PHA; PBL from 2 control patients, Table II . (Table II) . With a one-way analysis of variance, this result was not statistically different (P> 0.05) from the mean frequency observed in control subjects. In 26 of these patients, the mean frequency fell within the range 5.4-12.3 observed in the control subjects; further tests on these patients on 2-3 different occasions showed little variation and all individual mean test results fell within the normal range. In the remaining 4 patients, however, mean SCE frequencies fell outside the normal range, being 13.9, 14.3, 14.5 and 24.5; each of these 4 patients was tested on 2 separate occasions with consistent results in each case.
The mean SCE frequency of the 7 recipients with skin cancer from 2-4 different assays was 14.3 per cell which is significantly different (P<0.01) by the analysis of variance test from the mean result in control subjects.
The individual results of SCE assays in the 7 recipients with cancer are presented in Table III . Three patients had basal cell carcinoma (BCC); in 2 cases a single tumour and in 1 case, multiple tumours. Four patients had squamous cell carcinoma (SCC); in 1 case a single tumour, in another case multiple tumours, and in 2 cases, multiple recurring tumours. In 3 cases the mean SCE frequency (9.1-11.5) was within the range observed in control subjects, and in 4 cases (15.9-19.9) it was outside this control range. The degree of variability between repeated assays of the same individuals was within the limits of that seen for control subjects. In 8/37 transplant recipients, SCE rates were determined from PBL samples cultured for 96 h. Although SCE rates in PBL may increase with time in culture (Ockey, 1980) , in each of these 8 patients, the mean SCE frequency fell within the control range (5.4-12. 3).
The possibility that environmental factors outside those associated with transplantation and immunosuppressive therapy might influence SCE frequency was considered. Of the 8 patients whose mean SCE frequency exceeded the normal range, none had occupations considered "high-risk" for mutagenesis and only 1 was a cigarette smoker. There was also nothing to suggest that these 8 patients had greater than normal exposure to sunlight.
Discussion
In this study, PBL were selected because there are at present no appropriate measures for assaying chromosomal damage in human germ cells and therefore an extrapolation from a somatic cell must be used. Also studies on cultured mammalian cells and animals or humans exposed to mutagenic agents have shown that PBL provide reliable and sensitive indicators of both in vivo and in vitro induced chromosomal damage (Perry & Evans, 1975; Stetka et al., 1978) .
The mean rate of SCE in cultured lymphocytes from the general population as reported by other groups varies widely, between 5 and 14 per cell (Galloway & Evans, 1975; Dauod et al., 1976; Crossen et al., 1977; Raposa, 1978) . It is not clear how much of this variation is due to real differences in the various populations studied, but it is likely that much of it is artefactual, reflecting relatively small sample numbers and differences in culture and staining techniques. Similarly, values reported in those human conditions characterised by an elevated SCE frequency are variable but are generally in the order of a 2-3 fold increase following in vivo exposure to mutagenic agents (Nevstad, 1978; Raposa, 1978) .
The range and mean SCE frequency observed in control patients in this study is in general agreement with that reported by others. Moreover, the assay was reproducible, showing little variation with time in individuals. However, the intra-subject variation on a particular test occasion was high and is difficult to interpret although it has been observed before (Morgan & Crossen, 1977; Crossen et al., 1977) .
In this study we have investigated the potential genetic hazard to transplant recipients receiving immunosuppressive therapy. This may be of importance because of the increasing number of transplant recipients having children and the high incidence of cancer in transplant recipients. Eight of a total of 37 (22%) of renal transplant recipients showed elevated SCE rates suggesting in these patients exposure to mutagenic agents with consequent chromosomal damage. Whether these patients will be at increased risk of cancer development remains to be seen, but the finding that 4/7 patients with skin cancer had an increased frequency is suggestive that they might be. While the increase in SCE frequency in these patients is not dramatic, any chromosomal damage may add to other factors which predispose to malignancy such as exposure to sunlight or oncogenic viruses.
